JPWO2022066916A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022066916A5 JPWO2022066916A5 JP2023518356A JP2023518356A JPWO2022066916A5 JP WO2022066916 A5 JPWO2022066916 A5 JP WO2022066916A5 JP 2023518356 A JP2023518356 A JP 2023518356A JP 2023518356 A JP2023518356 A JP 2023518356A JP WO2022066916 A5 JPWO2022066916 A5 JP WO2022066916A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound
- formula
- pharma
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063082101P | 2020-09-23 | 2020-09-23 | |
| US63/082,101 | 2020-09-23 | ||
| PCT/US2021/051763 WO2022066916A1 (en) | 2020-09-23 | 2021-09-23 | Piperazine-based cationic lipids |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023542944A JP2023542944A (ja) | 2023-10-12 |
| JPWO2022066916A5 true JPWO2022066916A5 (enExample) | 2024-10-01 |
| JP7791182B2 JP7791182B2 (ja) | 2025-12-23 |
Family
ID=78414070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518356A Active JP7791182B2 (ja) | 2020-09-23 | 2021-09-23 | ピペラジンベースのカチオン性脂質 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230357166A1 (enExample) |
| EP (1) | EP4216933B1 (enExample) |
| JP (1) | JP7791182B2 (enExample) |
| KR (1) | KR20230074526A (enExample) |
| CN (1) | CN116457027A (enExample) |
| AU (1) | AU2021349262A1 (enExample) |
| BR (1) | BR112023005207A2 (enExample) |
| CA (1) | CA3193347A1 (enExample) |
| ES (1) | ES2994955T3 (enExample) |
| IL (1) | IL301536A (enExample) |
| MX (1) | MX2023003344A (enExample) |
| WO (1) | WO2022066916A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202233232A (zh) * | 2020-11-06 | 2022-09-01 | 法商賽諾菲公司 | 遞送mRNA疫苗的脂質奈米顆粒 |
| KR20230171974A (ko) * | 2021-04-15 | 2023-12-21 | 트랜슬레이트 바이오 인코포레이티드 | “good” 완충제-기반 양이온성 지질 |
| TW202345835A (zh) * | 2022-03-16 | 2023-12-01 | 美商轉譯生技公司 | 非對稱的基於哌嗪之陽離子脂質 |
| CN121318878A (zh) | 2022-04-13 | 2026-01-13 | 赛诺菲 | 基于“古德”缓冲液的阳离子脂质 |
| EP4594299A1 (en) * | 2022-09-27 | 2025-08-06 | Reinvigoron TheraTech, Inc. | Compounds with cleavable disulfide moieties |
| AR131438A1 (es) | 2022-12-20 | 2025-03-19 | Sanofi Sa | VACUNA DE ARNm DE RINOVIRUS |
| CN116082275B (zh) * | 2023-03-13 | 2023-07-14 | 北京悦康科创医药科技股份有限公司 | 一种脾脏中高表达的阳离子脂质化合物、包含其的组合物及用途 |
| CN121712487A (zh) | 2023-06-28 | 2026-03-20 | 赛诺菲巴斯德有限公司 | 脂质纳米颗粒配制品中的固醇类似物 |
| CN121219273A (zh) * | 2023-11-02 | 2025-12-26 | 深圳厚存纳米药业有限公司 | 脂质和脂质纳米颗粒制剂 |
| US12539279B2 (en) | 2023-12-11 | 2026-02-03 | The Governing Council Of The University Of Toronto | Supramolecular ionizable lipid molecules with heteroatomic tuning for nucleic acid delivery |
| WO2025141521A1 (en) | 2023-12-29 | 2025-07-03 | Sanofi | Lipids having dendritic moieties |
| WO2025160118A1 (en) * | 2024-01-22 | 2025-07-31 | The Trustees Of The University Of Pennsylvania | Compositions and methods for hematopoietic stem cell (hsc) targeted delivery of therapeutic agents |
| WO2025255534A1 (en) * | 2024-06-07 | 2025-12-11 | Innovac Therapeutics Hk Limited | Diol-based novel ionizable lipids and their uses thereof |
| WO2026008743A1 (en) | 2024-07-02 | 2026-01-08 | Sanofi Pasteur Inc. | Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid |
| WO2026053147A1 (en) | 2024-09-05 | 2026-03-12 | Sanofi Pasteur Inc. | Helper lipids and lnp compositions comprising same |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| US7101995B2 (en) * | 2001-08-27 | 2006-09-05 | Mirus Bio Corporation | Compositions and processes using siRNA, amphipathic compounds and polycations |
| CA2764609C (en) | 2009-06-10 | 2018-10-02 | Alnylam Pharmaceuticals, Inc. | Improved cationic lipid of formula i |
| CA2884870C (en) * | 2012-08-13 | 2022-03-29 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
| WO2015061467A1 (en) * | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Lipid formulations for delivery of messenger rna |
| AU2015279968B2 (en) * | 2014-06-24 | 2019-11-14 | Translate Bio, Inc. | Stereochemically enriched compositions for delivery of nucleic acids |
| CA2990172A1 (en) * | 2015-06-19 | 2016-12-22 | Massachusetts Institute Of Technology | Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell |
| PT3538515T (pt) * | 2016-11-08 | 2022-09-30 | Univ Ramot | Composto de pirimidina como inibidor de jak cinase |
| JP7738979B2 (ja) | 2016-11-10 | 2025-09-16 | トランスレイト バイオ， インコーポレイテッド | Ｍｒｎａ担持脂質ナノ粒子を調製する改善されたプロセス |
| WO2020023533A1 (en) * | 2018-07-23 | 2020-01-30 | Translate Bio, Inc. | Dry power formulations for messenger rna |
| JP7483294B2 (ja) * | 2018-11-09 | 2024-05-15 | トランスレイト バイオ， インコーポレイテッド | 層間エステル、チオエステル、ジスルフィドおよび無水部分を含む２，５－ジオキソピペラジン脂質 |
| WO2021226468A1 (en) * | 2020-05-07 | 2021-11-11 | Translate Bio, Inc. | Improved compositions for cftr mrna therapy |
| EP4146680A1 (en) * | 2020-05-07 | 2023-03-15 | Translate Bio, Inc. | Composition and methods for treatment of primary ciliary dyskinesia |
-
2021
- 2021-09-23 WO PCT/US2021/051763 patent/WO2022066916A1/en not_active Ceased
- 2021-09-23 EP EP21799143.9A patent/EP4216933B1/en active Active
- 2021-09-23 KR KR1020237013611A patent/KR20230074526A/ko not_active Withdrawn
- 2021-09-23 BR BR112023005207A patent/BR112023005207A2/pt unknown
- 2021-09-23 IL IL301536A patent/IL301536A/en unknown
- 2021-09-23 AU AU2021349262A patent/AU2021349262A1/en active Pending
- 2021-09-23 US US18/246,263 patent/US20230357166A1/en active Pending
- 2021-09-23 CN CN202180075719.XA patent/CN116457027A/zh active Pending
- 2021-09-23 MX MX2023003344A patent/MX2023003344A/es unknown
- 2021-09-23 JP JP2023518356A patent/JP7791182B2/ja active Active
- 2021-09-23 ES ES21799143T patent/ES2994955T3/es active Active
- 2021-09-23 CA CA3193347A patent/CA3193347A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022066916A5 (enExample) | ||
| JP2018519818A5 (enExample) | ||
| JP2025024002A5 (enExample) | ||
| JP2017536092A5 (enExample) | ||
| JP5355856B2 (ja) | Ｖｅｇｆアンタゴニストおよび抗増殖性薬剤の組成物ならびに癌の処置のためのその使用 | |
| JP2024023349A5 (enExample) | ||
| CN103269722A (zh) | 治疗性和/或诊断性纳米载体的靶向的适体缀合物 | |
| JP2005504749A5 (enExample) | ||
| JPWO2020097384A5 (enExample) | ||
| JP2009541236A5 (enExample) | ||
| JP2019519489A5 (enExample) | ||
| JPWO2022155530A5 (enExample) | ||
| JP2012507577A5 (enExample) | ||
| JP2006508045A (ja) | ヒト以外の動物のアポリポプロテインａ−ｉタンパク質の使用方法 | |
| JP2012513471A5 (enExample) | ||
| JP2014528411A5 (enExample) | ||
| JP2024500158A (ja) | １，２－ジオレオイル－３－トリメチルアンモニウム－プロパン（ｄｏｔａｐ）脂質ナノ粒子による組織特異的核酸送達 | |
| MX2013013014A (es) | Metodo para el tratamiento de tumores solidos avanzados. | |
| JP2006525368A5 (enExample) | ||
| JPWO2021202694A5 (enExample) | ||
| TWI760319B (zh) | 乳癌治療 | |
| JPWO2020069442A5 (enExample) | ||
| US20230035723A1 (en) | Treatment of Pancreatic Cancer | |
| JPWO2022066678A5 (enExample) | ||
| JPWO2023178167A5 (enExample) |